INT110343

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 22
Total Number 22
Disease Relevance 5.84
Pain Relevance 4.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (PIK3CD) signal transduction (PIK3CD) plasma membrane (PIK3CD)
Anatomy Link Frequency
MG-63 2
plasma 1
endothelial cell 1
blood platelets 1
HT-1080 1
PIK3CD (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 103 99.92 Very High Very High Very High
antagonist 33 99.36 Very High Very High Very High
agonist 82 98.64 Very High Very High Very High
Opioid 67 96.88 Very High Very High Very High
Bioavailability 6 94.72 High High
cINOD 40 94.36 High High
qutenza 6 90.24 High High
chemokine 9 89.32 High High
Enkephalin 40 87.92 High High
b2 receptor 9 86.56 High High
Disease Link Frequency Relevance Heat
Sarcoma 5 99.60 Very High Very High Very High
Osteogenic Sarcomas 4 99.44 Very High Very High Very High
Apoptosis 314 99.32 Very High Very High Very High
Glioblastoma 8 98.20 Very High Very High Very High
Obesity 68 97.08 Very High Very High Very High
Stomach Cancer 10 96.56 Very High Very High Very High
Leukemia 23 96.24 Very High Very High Very High
Pulmonary Disease 8 96.04 Very High Very High Very High
Cancer 313 94.16 High High
INFLAMMATION 195 94.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, sulindac and LY294002, a selective inhibitor of phosphoinositide 3-kinase (PI3K), synergistically inhibited the invasion of glioblastoma cells.
Negative_regulation (inhibitor) of PI3K associated with glioblastoma
1) Confidence 0.40 Published 2005 Journal J. Cell. Biochem. Section Abstract Doc Link 15546138 Disease Relevance 0.67 Pain Relevance 0.22
Phosphoinositide 3-kinase (PI3K), tyrosine kinase of the epidermal growth factor receptor (EGFR), and mitogen activated protein kinase kinases (MEK) inhibitors were also tested.
Negative_regulation (inhibitors) of Phosphoinositide 3-kinase
2) Confidence 0.37 Published 2004 Journal J. Cell. Physiol. Section Abstract Doc Link 15281091 Disease Relevance 0 Pain Relevance 0.44
Phosphoinositide 3-kinase (PI3K), tyrosine kinase of the epidermal growth factor receptor (EGFR), and mitogen activated protein kinase kinases (MEK) inhibitors were also tested.
Negative_regulation (inhibitors) of PI3K
3) Confidence 0.37 Published 2004 Journal J. Cell. Physiol. Section Abstract Doc Link 15281091 Disease Relevance 0 Pain Relevance 0.41
In addition, the BK induced cytosol-to-membrane translocation of PKC-delta was blocked by PI3K inhibition, suggesting that PI3K is upstream to PKC-delta.
Negative_regulation (inhibition) of PI3K associated with bradykinin
4) Confidence 0.37 Published 2004 Journal J. Cell. Physiol. Section Abstract Doc Link 15281091 Disease Relevance 0 Pain Relevance 0.34
RI-anti-IgE complex, a suggestion would come that the inhibition of PI3K leads to the loss of phosphorylation of downstream kinases such as Bruton's tyrosine kinase (BTK) [38] which in turn is able to phosphorylate PLC?
Negative_regulation (inhibition) of PI3K
5) Confidence 0.36 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2949734 Disease Relevance 0 Pain Relevance 0.06
The IC50 for quercetin as an inhibitor of PI3K from human blood platelets is around 1.8-20 ?
Negative_regulation (inhibitor) of PI3K in blood platelets
6) Confidence 0.36 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2949734 Disease Relevance 0 Pain Relevance 0
However, there is a conflict in our results, as the use of 2 different PI3K inhibitors leads to opposite effects.
Negative_regulation (inhibitors) of PI3K
7) Confidence 0.29 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2819999 Disease Relevance 0.24 Pain Relevance 0
What is really interesting is that the observed modulatory biphasic (hormetic) mechanism can be related to the inhibition of PI3K by quercetin and that the efficacious doses are within the nanomolar plasma concentrations reported in several pharmacokinetic and bioavailability studies about this flavonoid [51-53].
Negative_regulation (inhibition) of PI3K in plasma associated with bioavailability
8) Confidence 0.27 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2949734 Disease Relevance 0 Pain Relevance 0.08
These hypotheses and models need for further investigation on a molecular level such as a direct demonstration of the kinases isolated from or detected in the purified basophils and/or by using isoform-selective inhibitors of PI3K and to assay calmodulin involvement in the A23187 activation pathway inhibited by quercetin.
Negative_regulation (inhibitors) of PI3K in basophils
9) Confidence 0.27 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2949734 Disease Relevance 0 Pain Relevance 0.04
Previously published reports have shown that quercetin is able to inhibit PI3K by binding to the catalytic pocket of the enzyme: as for instance, LY294002, a synthetic inhibitor of PI3K, has actually a chemical kinship with the flavonoid quercetin [36].
Negative_regulation (inhibitor) of PI3K
10) Confidence 0.27 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2949734 Disease Relevance 0 Pain Relevance 0
LY294002, a phosphoinositide-3 kinase (PI3K)/AKT inhibitor, and Trolox, an antioxidant, suppressed indomethacin-induced cytotoxicity and caspase activation.
Negative_regulation (inhibitor) of PI3K
11) Confidence 0.26 Published 2007 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17341418 Disease Relevance 0.71 Pain Relevance 0.06
Similarly, the sensitivity to cisplatin was increased by celecoxib in a human osteosarcoma cell line (MG-63) and this effect was linked to a down-regulation of anti-apoptotic proteins survivin, Bcl-2, and an inhibition of the survival pathway PI3K/Akt [112].
Negative_regulation (inhibition) of PI3K in MG-63 associated with apoptosis and osteogenic sarcomas
12) Confidence 0.25 Published 2010 Journal International Journal of Cell Biology Section Body Doc Link PMC2841246 Disease Relevance 0.71 Pain Relevance 0.04
It is possible that the cytotoxicity of PO against HT-1080 observed in Fig. 5A could also be due to/associated with the inhibition of PI3K/AKT signaling (Fig. 5D).
Negative_regulation (inhibition) of PI3K in HT-1080
13) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925949 Disease Relevance 0.27 Pain Relevance 0.10
A PI3K inhibitor LY294002 significantly suppressed AKT phosphorylation and VEGF expression, which is similar to PO treatment, implying that PI3K is related to and downstream of VEGF in the cells.
Negative_regulation (inhibitor) of PI3K
14) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925949 Disease Relevance 0.23 Pain Relevance 0
Nakashio et al. also reported that Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-AKT signaling pathway [30].
Negative_regulation (downregulation) of PI3K in endothelial cell
15) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2925949 Disease Relevance 0.29 Pain Relevance 0.03
To determine the potential involvement of the PI3K pathway in the resensitization response to bradykinin, we applied the PI3K inhibitor LY294002 (50 ?
Negative_regulation (inhibitor) of PI3K associated with bradykinin
16) Confidence 0.19 Published 2010 Journal Cancer Cell Int Section Body Doc Link PMC2955562 Disease Relevance 0 Pain Relevance 0.40
Both chelation of intracellular calcium by BAPTA/AM (Fig. 6F) as well as pretreatment with the PI3K inhibitors (LY294002 and wortmannin, Fig. 6H) prevented Mycobacterium butyricum-induced opioid peptide release.
Negative_regulation (inhibitors) of PI3K associated with opioid
17) Confidence 0.11 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2657213 Disease Relevance 0.08 Pain Relevance 0.94
Celecoxib triggered also apoptosis in osteosarcoma cells (MG-63) through down-regulation of Bcl-2, survivin and PI3K (phosphoinositide 3-kinase) pathway [112].
Negative_regulation (regulation) of PI3K in MG-63 associated with osteogenic sarcomas and apoptosis
18) Confidence 0.08 Published 2010 Journal International Journal of Cell Biology Section Body Doc Link PMC2841246 Disease Relevance 1.23 Pain Relevance 0.10
This effect was blocked by the CB1 receptor antagonist SR141716A (0.5 microM), and by phosphoinositide-3-kinase and phospholipase C inhibitors.
Negative_regulation (inhibitors) of phosphoinositide-3-kinase associated with antagonist
19) Confidence 0.08 Published 2003 Journal Cell. Mol. Life Sci. Section Abstract Doc Link 12737320 Disease Relevance 0 Pain Relevance 0.60
Effects of phosphatidylinositide-3-kinase (PI3K) inhibitors and laminin-competing peptide, both of which are required for phenotype maturation, on DGC subunit abundance were measured.
Negative_regulation (inhibitors) of PI3K
20) Confidence 0.06 Published 2007 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2875553 Disease Relevance 0.28 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox